219 related articles for article (PubMed ID: 37842562)
1. Delta- like ligand 4- expressing macrophages and human diseases: Insights into pathophysiology and therapeutic opportunities.
Yuwen Y; Wang X; Liu J; Liu Z; Zhu H
Heliyon; 2023 Oct; 9(10):e20777. PubMed ID: 37842562
[TBL] [Abstract][Full Text] [Related]
2. Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation Via the Interplay of OATP2B1 and Dll4-Notch Signaling.
Nakano T; Katsuki S; Chen M; Decano JL; Halu A; Lee LH; Pestana DVS; Kum AST; Kuromoto RK; Golden WS; Boff MS; Guimaraes GC; Higashi H; Kauffman KJ; Maejima T; Suzuki T; Iwata H; Barabási AL; Aster JC; Anderson DG; Sharma A; Singh SA; Aikawa E; Aikawa M
Circulation; 2019 Jan; 139(1):78-96. PubMed ID: 30586693
[TBL] [Abstract][Full Text] [Related]
3. Delta-like 4 induces notch signaling in macrophages: implications for inflammation.
Fung E; Tang SM; Canner JP; Morishige K; Arboleda-Velasquez JF; Cardoso AA; Carlesso N; Aster JC; Aikawa M
Circulation; 2007 Jun; 115(23):2948-56. PubMed ID: 17533181
[TBL] [Abstract][Full Text] [Related]
4. Myeloid DLL4 Does Not Contribute to the Pathogenesis of Non-Alcoholic Steatohepatitis in Ldlr-/- Mice.
Jeurissen ML; Walenbergh SM; Houben T; Hendrikx T; Li J; Oligschlaeger Y; van Gorp PJ; Gijbels MJ; Bitorina A; Nessel I; Radtke F; Vooijs M; Theys J; Shiri-Sverdlov R
PLoS One; 2016; 11(11):e0167199. PubMed ID: 27898698
[TBL] [Abstract][Full Text] [Related]
5. Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development: Implications for the Treatment of Vein Graft Failure.
Koga JI; Nakano T; Dahlman JE; Figueiredo JL; Zhang H; Decano J; Khan OF; Niida T; Iwata H; Aster JC; Yagita H; Anderson DG; Ozaki CK; Aikawa M
Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2343-2353. PubMed ID: 26404485
[TBL] [Abstract][Full Text] [Related]
6. Notch signaling triggered via the ligand DLL4 impedes M2 macrophage differentiation and promotes their apoptosis.
Pagie S; Gérard N; Charreau B
Cell Commun Signal; 2018 Jan; 16(1):4. PubMed ID: 29321062
[TBL] [Abstract][Full Text] [Related]
7. Expanding role of delta-like 4 mediated notch signaling in cardiovascular and metabolic diseases.
Fukuda D; Aikawa M
Circ J; 2013; 77(10):2462-8. PubMed ID: 24025398
[TBL] [Abstract][Full Text] [Related]
8. Notch ligand delta-like 4 blockade attenuates atherosclerosis and metabolic disorders.
Fukuda D; Aikawa E; Swirski FK; Novobrantseva TI; Kotelianski V; Gorgun CZ; Chudnovskiy A; Yamazaki H; Croce K; Weissleder R; Aster JC; Hotamisligil GS; Yagita H; Aikawa M
Proc Natl Acad Sci U S A; 2012 Jul; 109(27):E1868-77. PubMed ID: 22699504
[TBL] [Abstract][Full Text] [Related]
9. Macrophages: The Good, the Bad, and the Gluttony.
Ross EA; Devitt A; Johnson JR
Front Immunol; 2021; 12():708186. PubMed ID: 34456917
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid Receptor 1 Blockade Attenuates Obesity and Adipose Tissue Type 1 Inflammation Through miR-30e-5p Regulation of Delta-Like-4 in Macrophages and Consequently Downregulation of Th1 Cells.
Miranda K; Mehrpouya-Bahrami P; Nagarkatti PS; Nagarkatti M
Front Immunol; 2019; 10():1049. PubMed ID: 31134094
[TBL] [Abstract][Full Text] [Related]
11. Expression of Notch signaling components in cutaneous foreign body and sarcoidal granulomas and fusing macrophages.
Rangel JR; Chung Y; Rosenbach M; Ziober AF; Zhang PJ; Schaffer A
Am J Dermatopathol; 2014 May; 36(5):409-13. PubMed ID: 24394305
[TBL] [Abstract][Full Text] [Related]
12. PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors.
Iwamoto H; Zhang Y; Seki T; Yang Y; Nakamura M; Wang J; Yang X; Torimura T; Cao Y
Sci Adv; 2015 Apr; 1(3):e1400244. PubMed ID: 26601163
[TBL] [Abstract][Full Text] [Related]
13. The Notch ligand Delta-like 4 (DLL4) as a target in angiogenesis-based cancer therapy?
Brzozowa M; Wojnicz R; Kowalczyk-Ziomek G; Helewski K
Contemp Oncol (Pozn); 2013; 17(3):234-7. PubMed ID: 24596507
[TBL] [Abstract][Full Text] [Related]
14. [Influence of Delta-like ligand 4/Notch signal transduction pathway upon the biological behavior of human umbilical vein endothelial cells].
Chen L; Lü W; Wei B; Wang N; Li T
Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(44):3106-10. PubMed ID: 20193271
[TBL] [Abstract][Full Text] [Related]
15. Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature.
Leach A; Smyth P; Ferguson L; Steven J; Greene MK; Branco CM; McCann AP; Porter A; Barelle CJ; Scott CJ
Nanoscale; 2020 Jul; 12(27):14751-14763. PubMed ID: 32626858
[TBL] [Abstract][Full Text] [Related]
16. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
Silkenstedt E; Arenas F; Colom-Sanmartí B; Xargay-Torrent S; Higashi M; Giró A; Rodriguez V; Fuentes P; Aulitzky WE; van der Kuip H; Beà S; Toribio ML; Campo E; López-Guerra M; Colomer D
J Exp Clin Cancer Res; 2019 Nov; 38(1):446. PubMed ID: 31676012
[TBL] [Abstract][Full Text] [Related]
17. Monocyte-derived Dll4 is a novel contributor to persistent systemic inflammation in HIV patients.
Wang S; Singh M; Yang H; Morrell CN; Mohamad LA; Xu JJ; Nguyen T; Ture S; Tyrell A; Maggirwar SB; Schifitto G; Pang J
bioRxiv; 2023 Apr; ():. PubMed ID: 37131726
[TBL] [Abstract][Full Text] [Related]
18. Delta-like ligand 4 identifies a previously uncharacterized population of inflammatory dendritic cells that plays important roles in eliciting allogeneic T cell responses in mice.
Mochizuki K; Xie F; He S; Tong Q; Liu Y; Mochizuki I; Guo Y; Kato K; Yagita H; Mineishi S; Zhang Y
J Immunol; 2013 Apr; 190(7):3772-82. PubMed ID: 23440416
[TBL] [Abstract][Full Text] [Related]
19. Influence of specific blocking of the delta-like ligand 4/notch signal transduction pathway on the biological behavior of human umbilical vein endothelial cells.
Lv W; Chen L; Zhou DH; Wei B
Cancer Biother Radiopharm; 2010 Aug; 25(4):449-54. PubMed ID: 20701540
[TBL] [Abstract][Full Text] [Related]
20. Macrophage: A Key Therapeutic Target in Atherosclerosis?
Taghizadeh E; Taheri F; Renani PG; Reiner Ž; Navashenaq JG; Sahebkar A
Curr Pharm Des; 2019; 25(29):3165-3174. PubMed ID: 31470780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
